Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04875351 · ClinicalTrials.gov registry record
Breast Cancer Index (BCI) Registry
A clinical trial of Breast Cancer, sponsored by Biotheranostics.
- Active
- Registry status
- 3,465
- Enrollment target
- 20
- Study locations
NCT04875351: Active study of Breast Cancer, sponsored by Biotheranostics.
NCT04875351 is a study of Breast Cancer that is active but no longer recruiting, run by Biotheranostics. The registered enrollment target is 3,465 participants, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (24% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04875351, a study of Breast Cancer, is active but no longer recruiting, sponsored by Biotheranostics.
- ACTIVE NOT RECRUITING
- Registry status
- 3,465 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
Study Locations (20)
Colorado
- Rocky Mountain Cancer Center - Aurora - Aurora
- Rocky Mountain Cancer Center - Boulder - Boulder
- Rocky Mountain Cancer Center - Centennial - Centennial
- Rocky Mountain Cancer Center - Colorado Springs - Colorado Springs
- Rocky Mountain Cancer Center - Denver Midtown - Denver
- Rocky Mountain Cancer Center - Denver - Denver
- Rocky Mountain Cancer Center - Swedish Medical Center - Englewood
- Rocky Mountain Cancer Centers - Lakewood - Lakewood
Arizona
- Arizona Oncology Associates, PC - Glendale - Saguaro Cancer Center - Glendale
- Arizona Oncology Associates, PC - Goodyear - Goodyear
- Arizona Oncology Associates, PC - Phoenix - Biltmore Cancer Center - Phoenix
- Arizona Oncology Associates, PC - Phoenix - Deer Valley - Phoenix
- Arizona Oncology Associates, PC - Scottsdale - Scottsdale
- Arizona Oncology Associates, PC - East Valley Cancer Center - Tempe
Alabama
- Southern Cancer Center, P.C. - Daphne - Daphne
- Southern Cancer Center, PC - Mobile Infirmary - Mobile
- Southern Cancer Center, PC - Providence Hospital - Mobile
- Southern Cancer Center, PC - Springhill Medical Center - Mobile
California
- Sansum Clinic - Ridley-Tree Cancer Center - Santa Barbara
- Sansum Clinic - Ridley-Tree Cancer Center (Solvang) - Solvang
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,465 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2028-12 |
What the registry record for NCT04875351 still lists
NCT04875351 is an observational study that tracks outcomes without assigning an intervention. Its 3,465 participants enrollment target places it among the larger protocols in the corpus, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is the first listed.
NCT04875351 names 20 study sites across 4 states, led by Colorado, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT04875351 about?
NCT04875351 is a clinical study titled "Breast Cancer Index (BCI) Registry". The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients recei...
What is the current status of trial NCT04875351?
This trial is currently active not recruiting. The enrollment target is 3,465 participants. The study started on 2021-04-14. Estimated completion is 2028-12.
What conditions does trial NCT04875351 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04875351?
The interventions under investigation include: Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04875351?
This trial is sponsored by Biotheranostics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04875351 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04875351's enrollment target sits among peer trials
3,465 42nd of 1224 higher than 1,183 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI